Table 3 Diagnostic accuracy metrics: pooled sensitivities and specificities of index tests stratified by study characteristics.
Study characteristic | Parameter | Number of study arms | Sensitivity | Specificity | ||
|---|---|---|---|---|---|---|
TP + FN | (95% CI) | TN + FP | (95% CI) | |||
Immunoglobulins | ||||||
|  | Anti-HDV IgG | 9 | 342 | 97.4 (94.6–100.0) | 1060 | 95.3 (94.0–96.6) |
|  | Total Anti-HDV | 1 | 79 | 51.9 (40.9–62.9) | 40 | 80.0 (67.6–92.4) |
|  | Anti-HDV IgM | 1 | 79 | 62.0 (51.3–72.7) | 40 | 85.0 (73.9–96.1) |
Index test | ||||||
|  | Architect immune assay | 1 | 16 | 100.0 (76.9–100.0) | 129 | 94.6 (90.7–98.5) |
|  | EIA | 1 | 79 | 62.0 (51.3–72.7) | 40 | 85.0 (73.9–96.1) |
|  | ELISA | 4 | 134 | 94.8 (89.7–100.0) | 731 | 95.6 (94.1–97.0) |
|  | QMAC | 2 | 96 | 97.2 (92.1–100.0) | 100 | 92.0 (85.4–98.5) |
|  | RIA | 1 | 79 | 51.9 (40.9–62.9) | 40 | 80 (67.6–92.4) |
|  | Western blot | 2 | 96 | 100.0 (95.1–100.0) | 100 | 95.3 (89.7–100.0) |
Brand of index test | ||||||
|  | Commercial assays | 4 | 244 | 80.1 (75.4–84.7) | 262 | 95.2 (92.8–97.7) |
|  | In-house assays | 7 | 256 | 98.8 (95.5–100.0) | 878 | 94.9 (− 93.4–96.6) |
Anti HDV IgG by the brand of test | ||||||
|  | Commercial anti-HDV IgG | 2 | 86 | 93.3 (87.5–99.2) | 182 | 96.4 (93.9–99.0) |
|  | In-house anti-HDV IgG | 7 | 256 | 98.8 (95.5–100.0) | 878 | 94.9 (93.4–96.4) |
